Skip Navigation


JAC Advance Access originally published online on March 27, 2009
Journal of Antimicrobial Chemotherapy 2009 63(6):1097-1103; doi:10.1093/jac/dkp092
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
63/6/1097    most recent
dkp092v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hosseini-Moghaddam, S. M.
Right arrow Articles by Alavian, S. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hosseini-Moghaddam, S. M.
Right arrow Articles by Alavian, S. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Review

Is β-interferon a promising therapeutic option for the management of hepatitis C?

Seyed Mohammadmehdi Hosseini-Moghaddam1,*, Afkham Mousavi1 and Seyed Moayed Alavian2

1 Urology and Nephrology Research Center (UNRC), Shahid Beheshti University, M.C. (SBMU), Tehran, I.R. Iran 2 Baqiyatallah Research Center for Gastroenterology and Liver Disease, Baqiyatallah University of Medical Sciences, Tehran, I.R. Iran

* Corresponding author. UNRC, No. 44, Boostan 9th Street, Pasdaran Avenue, Tehran, I.R. Iran. Tel: +98-21-22567222; Fax: +98-21-22567282; E-mail: h_sasan{at}hotmail.com

Using interferon-alpha (IFN-{alpha}) as the conventional therapeutic antiviral drug, physicians generally achieve a treatment success of <50% in cases with chronic hepatitis C. Owing to the structural similarities between IFN-{alpha} and interferon-beta (IFN-β), the latter is a candidate for obtaining sustained viral response. In this review, we have compiled the published information on the use of IFN-β for the management of acute and chronic hepatitis C up to 2007. We have looked at the rates of success and side effects. IFN-β might be helpful if IFN-{alpha} fails to achieve a favourable outcome. This antiviral drug may be helpful for the management of chronic hepatitis C in both age extremes, in case of a relapse after receiving IFN-{alpha} and for preventing the development of the carrier state after acute hepatitis C. Further studies are required on the efficacy of IFN-β for the management of acute and chronic hepatitis C.

Keywords: HCV , cytokines , haemodialysis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.